Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company dedicated to addressing ototoxicity (hearing loss) in cancer patients, particularly pediatric patients, undergoing cisplatin-based chemotherapy. The company's headquarters are located in Research Triangle Park, Durham, North Carolina, United States.

Its primary product is PEDMARK® (sodium thiosulfate injection), which is the first and only FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged one month and older with localized, non-metastatic solid tumors. Fennec also commercializes PEDMARQSI® in Europe and the U.K. through an exclusive licensing agreement with Norgine Pharmaceuticals Ltd.

Fennec Pharmaceuticals has recently strengthened its executive leadership, with Jeff Hackman appointed CEO in August 2024, followed by additional key appointments in October 2024 to its leadership team. The company reported record annual revenue of $44.6 million for the full year 2025, marking a 50% year-over-year growth, driven by increased adoption of PEDMARK. Fennec continues to expand the clinical evidence for PEDMARK through investigator-initiated studies, evaluating its utility in adolescent, young adult, and adult cancer patients in collaborations with institutions such as Tampa General Hospital Cancer Institute and City of Hope.